Published in Cancer Weekly, November 22nd, 1999
Isis scientists successfully used an antisense oligonucleotide to both increase and decrease the levels of two functionally antagonistic proteins encoded by the Bcl-x gene, one of which is involved in the development of resistance in human tumors to chemotherapeutic agents used to treat cancer. Isis's antisense drugs exploiting this newly found mechanism and inhibiting Bcl-x have the potential to be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.